The Door That Will Not Close: Hepcidin, the HFE Gene, and Hereditary Hemochromatosis

Key Takeaways:

• Hepcidin is the hormone that closes ferroportin, the only exit iron has out of the gut lining; in HFE C282Y homozygotes that signal fails and absorption never switches off.
• C282Y homozygosity is common in people of northern European ancestry, but clinical penetrance is incomplete — in a cohort of more than 450,000 adults, only about twelve percent of C282Y homozygous men carried a hemochromatosis diagnosis at a mean age of fifty-seven.
• A fasting transferrin saturation above forty-five percent, paired with ferritin, is the screen; phlebotomy begun before cirrhosis or diabetes appear restores a normal life expectancy.

Iron has exactly one way out of the cells that absorb it. That exit is ferroportin, the sole known cellular iron exporter, and the hormone hepcidin is the hand on the latch — when body iron is sufficient, the liver releases hepcidin, hepcidin binds ferroportin, and the door closes. Hereditary hemochromatosis is what happens when that latch stops working. Homozygous C282Y mutation in the HFE gene blunts hepcidin production, ferroportin stays open, and iron keeps crossing from the duodenal lining into plasma with no braking signal, regardless of how much the body already holds. The surplus does not circulate harmlessly; it deposits in parenchymal tissue, and the organs that take the load are the liver, the pancreatic islets, the cardiomyocytes, the joints, and sometimes the pituitary. That distribution explains the strange clinical picture — a bronze-tinged patient with aching second and third knuckles, an unexplained cardiomyopathy, or diabetes that arrives without the usual metabolic story. A second variant, H63D, is far milder and rarely causes overload on its own; compound heterozygotes usually need a second insult before iron accumulates.

The nuance that matters, and the one most often lost, is that the genotype is not the disease. C282Y homozygosity is the most common recognized genetic variant in populations of northern European descent, yet a large share of homozygotes live full lives and never load iron to a damaging degree. In a prospective community cohort of more than 450,000 adults, only about twelve percent of C282Y homozygous men had a hemochromatosis diagnosis at a mean age of fifty-seven, with a cumulative incidence rising to roughly fifty-six percent by age eighty; in women, whose menstrual and pregnancy losses provide decades of unintentional phlebotomy, penetrance was lower still. So the gene is a risk multiplier, not a verdict — which is precisely why the diagnosis is made from biochemistry rather than from a genotype report alone. The two numbers that carry the weight are fasting transferrin saturation, which reflects how much iron is riding in plasma right now, and ferritin, which reflects how much has already been stored. Saturation is the earlier and more specific signal; ferritin is an acute-phase reactant that inflammation, alcohol, and fatty liver will lift on their own.

Who should be screened for hereditary hemochromatosis?

July is Hemochromatosis Awareness Month, and the screening logic is refreshingly simple: check a fasting transferrin saturation and a ferritin. A saturation above forty-five percent that persists on a repeat draw, in the company of a raised ferritin, warrants HFE genotyping — and in a confirmed C282Y homozygote those biochemical findings alone are enough to make the diagnosis. The people worth testing are first-degree relatives of anyone with the condition, and any adult presenting with unexplained fatigue, arthropathy of the index and middle knuckles, abnormal liver enzymes, early-onset diabetes, or a cardiomyopathy without a cause. Treatment is deliberately low-tech: therapeutic phlebotomy, weekly at first, until ferritin falls below fifty, then a maintenance schedule to hold it under a hundred. Here honesty matters more than enthusiasm. Phlebotomy started in the precirrhotic stage is transformative — the classic survival data show that hemochromatosis patients without cirrhosis or diabetes have a life expectancy indistinguishable from the general population, while those already cirrhotic at diagnosis do not recover that ground and carry a durable liver-cancer risk. Iron depletion prevents the damage it beats to the punch; it does not undo a fibrotic liver. That asymmetry is the entire argument for testing early rather than waiting for symptoms, because the whole disease turns on the difference between a door closed in time and a door closed too late.

References:

1. Brissot, P., Pietrangelo, A., Adams, P. C., de Graaff, B., McLaren, C. E., & Loréal, O. (2018). Haemochromatosis. Nature Reviews Disease Primers, 4, 18016.
2. Lucas, M. R., Atkins, J. L., Pilling, L. C., Shearman, J. D., & Melzer, D. (2024). HFE genotypes, haemochromatosis diagnosis and clinical outcomes at age 80 years: A prospective cohort study in the UK Biobank. BMJ Open, 14(3), e081926.
3. European Association for the Study of the Liver. (2022). EASL Clinical Practice Guidelines on haemochromatosis. Journal of Hepatology, 77(2), 479-502.
4. Niederau, C., Fischer, R., Sonnenberg, A., Stremmel, W., Trampisch, H. J., & Strohmeyer, G. (1985). Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. The New England Journal of Medicine, 313(20), 1256-1262.